Williams A, Mauro C, Chiodo L, Huber B, Cruz A, Crystal S
Drug Alcohol Depend. 2024; 263:112389.
PMID: 39154558
PMC: 11384240.
DOI: 10.1016/j.drugalcdep.2024.112389.
Fine D, Hart K, Critchley N, Chang Y, Regan S, Joyce A
J Gen Intern Med. 2024; 39(15):2927-2934.
PMID: 38987479
PMC: 11576663.
DOI: 10.1007/s11606-024-08916-2.
Hawkins E, Malte C, Hagedorn H, Gordon A, Williams E, Trim R
J Addict Med. 2024; 18(3):240-247.
PMID: 38329814
PMC: 11150106.
DOI: 10.1097/ADM.0000000000001275.
Martin A, Perryman T, Bernstein J, Taylor J, Cruz R, Muroff J
Drug Alcohol Depend Rep. 2023; 7:100156.
PMID: 37113387
PMC: 10126838.
DOI: 10.1016/j.dadr.2023.100156.
Ganapathi L, McFall A, Greco K, Srikrishnan A, Kumar M, Mayer K
Drug Alcohol Depend. 2023; 246:109839.
PMID: 37031487
PMC: 10416117.
DOI: 10.1016/j.drugalcdep.2023.109839.
Use of a sequential multiple assignment randomized trial to test contingency management and an integrated behavioral economic and mindfulness intervention for buprenorphine-naloxone medication adherence for opioid use disorder.
Peter S, Murphy J, Witkiewitz K, Hand S, Thomas F, Johnson K
Trials. 2023; 24(1):237.
PMID: 36991453
PMC: 10061866.
DOI: 10.1186/s13063-023-07102-9.
A Prescription Digital Therapeutic to Support Unsupervised Buprenorphine Initiation for Patients With Opioid Use Disorder: Protocol for a Proof-of-Concept Study.
Luderer H, Enman N, Gerwien R, Braun S, McStocker S, Xiong X
JMIR Res Protoc. 2023; 12:e43122.
PMID: 36662568
PMC: 9898828.
DOI: 10.2196/43122.
Cost-effectiveness of office-based buprenorphine treatment for opioid use disorder.
Qian G, Rao I, Humphreys K, Owens D, Brandeau M
Drug Alcohol Depend. 2023; 243:109762.
PMID: 36621198
PMC: 9852082.
DOI: 10.1016/j.drugalcdep.2022.109762.
The association between buprenorphine treatment duration and mortality: a multi-site cohort study of people who discontinued treatment.
Glanz J, Binswanger I, Clarke C, Nguyen A, Ford M, Ray G
Addiction. 2022; 118(1):97-107.
PMID: 35815386
PMC: 9722535.
DOI: 10.1111/add.15998.
Analysis of genetic and clinical factors associated with buprenorphine response.
Crist R, Vickers-Smith R, Kember R, Rentsch C, Xu H, Edelman E
Drug Alcohol Depend. 2021; 227:109013.
PMID: 34488071
PMC: 9328121.
DOI: 10.1016/j.drugalcdep.2021.109013.
Mobile Telemedicine for Buprenorphine Treatment in Rural Populations With Opioid Use Disorder.
Weintraub E, Seneviratne C, Anane J, Coble K, Magidson J, Kattakuzhy S
JAMA Netw Open. 2021; 4(8):e2118487.
PMID: 34448869
PMC: 8397932.
DOI: 10.1001/jamanetworkopen.2021.18487.
An Effective and Safe Novel Treatment of Opioid Use Disorder: Unilateral Transcranial Photobiomodulation.
Schiffer F, Khan A, Bolger E, Flynn E, Seltzer W, Teicher M
Front Psychiatry. 2021; 12:713686.
PMID: 34447323
PMC: 8382852.
DOI: 10.3389/fpsyt.2021.713686.
Office-Based Addiction Treatment Retention and Mortality Among People Experiencing Homelessness.
Fine D, Lewis E, Weinstock K, Wright J, Gaeta J, Baggett T
JAMA Netw Open. 2021; 4(3):e210477.
PMID: 33662132
PMC: 7933994.
DOI: 10.1001/jamanetworkopen.2021.0477.
A Mobile Health App to Support Patients Receiving Medication-Assisted Treatment for Opioid Use Disorder: Development and Feasibility Study.
Waselewski M, Flickinger T, Canan C, Harrington W, Franklin T, Otero K
JMIR Form Res. 2021; 5(2):e24561.
PMID: 33620324
PMC: 7943342.
DOI: 10.2196/24561.
Three-month outcomes from a patient-centered program to treat opioid use disorder in Iowa, USA.
Lynch A, Weber A, Hedden S, Sabbagh S, Arndt S, Acion L
Subst Abuse Treat Prev Policy. 2021; 16(1):8.
PMID: 33435993
PMC: 7801772.
DOI: 10.1186/s13011-021-00342-5.
Feasibility and Preliminary Efficacy of Isradipine During Outpatient Buprenorphine Stabilization and Detoxification: A Pilot Randomized, Placebo-Controlled Trial.
Kumar N, Mancino M, Thostenson J, McGaugh J, Oliveto A
Subst Abuse. 2020; 14:1178221820970926.
PMID: 33281447
PMC: 7686602.
DOI: 10.1177/1178221820970926.
Craving mediates the association between momentary pain and illicit opioid use during treatment for opioid-use disorder: an ecological momentary assessment study.
Mun C, Finan P, Epstein D, Kowalczyk W, Agage D, Letzen J
Addiction. 2020; 116(7):1794-1804.
PMID: 33220102
PMC: 8137724.
DOI: 10.1111/add.15344.
Safety and efficacy of a prescription digital therapeutic as an adjunct to buprenorphine for treatment of opioid use disorder.
Maricich Y, Bickel W, Marsch L, Gatchalian K, Botbyl J, Luderer H
Curr Med Res Opin. 2020; 37(2):167-173.
PMID: 33140994
PMC: 8666102.
DOI: 10.1080/03007995.2020.1846022.
Same-day vs. delayed buprenorphine prescribing and patient retention in an office-based buprenorphine treatment program.
Jakubowski A, Lu T, DiRenno F, Jadow B, Giovanniello A, Nahvi S
J Subst Abuse Treat. 2020; 119:108140.
PMID: 33138925
PMC: 7609975.
DOI: 10.1016/j.jsat.2020.108140.
Facilitators and barriers to utilization of medications for opioid use disorder in primary care in South Carolina.
Oros S, Christon L, Barth K, Berini C, Padgett B, Diaz V
Int J Psychiatry Med. 2020; 56(1):14-39.
PMID: 32726568
PMC: 10954352.
DOI: 10.1177/0091217420946240.